Dominari Holdings (Dominari Holdings) Pre-Tax Income

: $-22.88 Mil (TTM As of Dec. 2023)

View and export this data going back to 1984. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Dominari Holdings's pretax income for the three months ended in Dec. 2023 was $-6.92 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.88 Mil. Dominari Holdings's pretax margin was -688.16%.

During the past 13 years, Dominari Holdings's highest Pretax Margin was 6167.86%. The lowest was -305320.00%. And the median was -1122.22%.

Dominari Holdings Pre-Tax Income Historical Data

The historical data trend for Dominari Holdings's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dominari Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-4.18

-12.34

-7.17

-22.11

-22.88

Dominari Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-7.26	-3.76	-8.66	-3.54	-6.92

Competitive Comparison

For the Biotechnology subindustry, Dominari Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dominari Holdings Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Dominari Holdings's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's Pre-Tax Income falls into.

Dominari Holdings Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Dominari Holdings's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-21.796	+	-1.802	+	0	+	0.716	+	-3.5527136788005E-15
	=	-22.88

Dominari Holdings's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-5.847	+	-1.28	+	0	+	0.211	+	0
	=	-6.92

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.88 Mil.

Dominari Holdings (NAS:DOMH) Pre-Tax Income Explanation

Dominari Holdings's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-6.916	/	1.005
	=	-688.16%

During the past 13 years, Dominari Holdings's highest Pretax Margin was 6167.86%. The lowest was -305320.00%. And the median was -1122.22%.

Dominari Holdings Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Dominari Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Dominari Holdings (Dominari Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (NAS:DOMH) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

BP2A:Germany

Address

One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020

Website

https://www.dominariholdings.com

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Executives

Kyle Michael Wool	director	650 5TH AVE, 35TH FLOOR, NEW YORK NY 10019
Christopher Franklin Devall	officer: Chief Operating Officer	DOMINARI HOLDINGS INC., ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Anthony Hayes	director, officer: Chief Executive Officer	1796 SHADY LANE, COLUMBIA SC 29206
George Way	officer: Chief Financial Officer	C/O DOMINARI HOLDINGS INC., 725 5TH AVENUE 23RD FLOOR, NEW YORK NY 10022
Soo Yu	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Tim S Ledwick	director	10200 INNOVATION DRIVE, SUITE 300, MILWAUKEE WI 53226
Gregory James Blattner	director	ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY 10020
Paul Lemire	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Robert Frederick Dudley	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Zanden Robert J Vander	director	913 HIGH KNOLL WAY, TRAVELERS REST SC 29690
Eric Weisblum	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Howard E Goldberg	director	781 THIRD AVENUE, KING OF PRUSSIA PA 194061409
Frank Reiner	officer: Interim CFO	6430 ROCKLEDGE DRIVE, SUITE 503, BETHESDA MD 20817
Jeffrey Ballabon	director	6430 ROCKLEDGE DRIVE, BETHESDA NY 20817
Richard Cohen	officer: Chief Financial Officer	C/O DUNE ENERGY, INC., TWO SHELL PLAZA, 777 WALKER STREET, SUITE 2300, HOUSTON TX 77002